Chinese biotech Akeso disclosed that its PD-1xVEGF bispecific antibody ivonescimab significantly improved overall survival as second-line therapy combined with chemotherapy in advanced non-small cell lung cancer patients whose tumors progressed on EGFR-targeted treatments. Additionally, Akeso announced positive phase III results for antibodies targeting ankylosing spondylitis and atopic dermatitis, advancing regulatory filings and pipeline diversification.